Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: A randomized, placebo-controlled study
(2005) In Gastroenterology 128(7). p.1805-1811- Abstract
- Background & Aims: Despite treatment with corticosteroids, severe to moderately severe attacks of ulcerative colitis have a high colectomy rate. We intended to find a rescue therapy other than cyclosporin A, which imposes a high risk of side effects and cyclosporine-related mortality. Method : This was a randomized double-blind trial of infliximab or placebo in severe to moderately severe ulcerative colitis not responding to conventional treatment. Patients were randomized to infliximab/placebo either on day 4 after the initiation of corticosteroid treatment if they fulfilled the index criteria for fulminant ulcerative colitis on day 3 or on day 6-8 if they fulfilled index criteria on day 5-7 for a severe or moderately severe acute... (More)
- Background & Aims: Despite treatment with corticosteroids, severe to moderately severe attacks of ulcerative colitis have a high colectomy rate. We intended to find a rescue therapy other than cyclosporin A, which imposes a high risk of side effects and cyclosporine-related mortality. Method : This was a randomized double-blind trial of infliximab or placebo in severe to moderately severe ulcerative colitis not responding to conventional treatment. Patients were randomized to infliximab/placebo either on day 4 after the initiation of corticosteroid treatment if they fulfilled the index criteria for fulminant ulcerative colitis on day 3 or on day 6-8 if they fulfilled index criteria on day 5-7 for a severe or moderately severe acute attack of ulcerative colitis. Results were analyzed according to the intention-to-treat principle. The primary end point was colectomy or death 3 months after randomization. Secondary end points were clinical and endoscopic remission at that time in patients who did not undergo operation. Results: Forty-five patients were included (24 infliximab and 21 placebo). No patient died. Seven patients in the infliximab group and :14 in the placebo group had a colectomy (P = .017; odds ratio, 4.9; 95% confidence interval, 1.4-17) within 3 months after randomization. No serious side effects occurred. Three patients in the placebo group required operation for septic complications. Conclusions: Infliximab 4-5 mg/kg is an effective and safe rescue therapy in patients experiencing an acute severe or moderately severe attack of ulcerative colitis not responding to conventional treatment. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/237483
- author
- organization
- publishing date
- 2005
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Gastroenterology
- volume
- 128
- issue
- 7
- pages
- 1805 - 1811
- publisher
- Elsevier
- external identifiers
-
- pmid:15940615
- wos:000229662900007
- scopus:20444479336
- ISSN
- 1528-0012
- DOI
- 10.1053/j.gastro.2005.03.003
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Emergency medicine/Medicine/Surgery (013240200), Medicine (Lund) (013230025)
- id
- 5ac9e7ef-6d79-48fc-bead-23e45d7fe084 (old id 237483)
- date added to LUP
- 2016-04-01 12:22:59
- date last changed
- 2022-05-07 01:39:48
@article{5ac9e7ef-6d79-48fc-bead-23e45d7fe084,
abstract = {{Background & Aims: Despite treatment with corticosteroids, severe to moderately severe attacks of ulcerative colitis have a high colectomy rate. We intended to find a rescue therapy other than cyclosporin A, which imposes a high risk of side effects and cyclosporine-related mortality. Method : This was a randomized double-blind trial of infliximab or placebo in severe to moderately severe ulcerative colitis not responding to conventional treatment. Patients were randomized to infliximab/placebo either on day 4 after the initiation of corticosteroid treatment if they fulfilled the index criteria for fulminant ulcerative colitis on day 3 or on day 6-8 if they fulfilled index criteria on day 5-7 for a severe or moderately severe acute attack of ulcerative colitis. Results were analyzed according to the intention-to-treat principle. The primary end point was colectomy or death 3 months after randomization. Secondary end points were clinical and endoscopic remission at that time in patients who did not undergo operation. Results: Forty-five patients were included (24 infliximab and 21 placebo). No patient died. Seven patients in the infliximab group and :14 in the placebo group had a colectomy (P = .017; odds ratio, 4.9; 95% confidence interval, 1.4-17) within 3 months after randomization. No serious side effects occurred. Three patients in the placebo group required operation for septic complications. Conclusions: Infliximab 4-5 mg/kg is an effective and safe rescue therapy in patients experiencing an acute severe or moderately severe attack of ulcerative colitis not responding to conventional treatment.}},
author = {{Jarnerot, G and Hertervig, Erik and Friis-Liby, I and Blomquist, L and Karle, P and Granno, C and Vilien, M and Strom, M and Danielsson, A and Verbaan, Hans and Hellstrom, PM and Magnuson, A and Curman, B}},
issn = {{1528-0012}},
language = {{eng}},
number = {{7}},
pages = {{1805--1811}},
publisher = {{Elsevier}},
series = {{Gastroenterology}},
title = {{Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: A randomized, placebo-controlled study}},
url = {{http://dx.doi.org/10.1053/j.gastro.2005.03.003}},
doi = {{10.1053/j.gastro.2005.03.003}},
volume = {{128}},
year = {{2005}},
}